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Severe acute respiratory syndrome (SARS) is a life-threatening infectious disease which has been difficult to
study and treat because of the lack of a readily available animal model. Intranasal infection of A/J mice with
the coronavirus murine hepatitis virus strain 1 (MHV-1) produced pulmonary pathological features of SARS.
All MHV-1-infected A/J mice developed progressive interstitial pneumonitis, including dense macrophage
infiltrates, giant cells, and hyaline membranes, resulting in death of all animals. In contrast, other mouse
strains developed only mild transitory disease. Infected A/J mice had significantly higher cytokine levels,
particularly macrophage chemoattractant protein 1 (MCP-1/CCL-2), gamma interferon, and tumor necrosis
factor alpha. Furthermore, FGL2/fibroleukin mRNA transcripts and protein and fibrin deposits were markedly
increased in the lungs of infected A/J mice. These animals developed a less robust type I interferon response
to MHV-1 infection than resistant C57BL/6J mice, and treatment with recombinant beta interferon improved
survival. This study describes a potentially useful small animal model of human SARS, defines its pathogen-
esis, and suggests treatment strategies.
Severe acute respiratory syndrome (SARS) was first diag-
nosed in China in November 2002 and quickly spread to
Hong Kong, Singapore, Vietnam, Taiwan, and Canada (15,
20, 42). SARS was documented in approximately 8,000 per-
sons globally and resulted in over 700 deaths. Outbreaks in
research laboratory personnel and the recent discovery of a
new reservoir of the etiologic virus argue that further out-
breaks will arise (21).
The causative agent, SARS coronavirus (SARS-CoV), best
fits within group 2 coronaviruses, which include the mouse
hepatitis viruses (MHV) (6, 12, 15). The clinical severity of
SARS varied considerably, presumably because of the genetic
diversity of the host immune response (26). Considerable vari-
ation among SARS patients with respect to circulating viral
load and patterns of SARS-CoV-evoked cytokine responses
have been reported, although serum levels of gamma inter-
feron (IFN-), IL-10, CXCL10 (IP-10), CCL5 (RANTES), and
CXCL8 (IL-8) were elevated in most patients(54). However,
the underlying pathogenetic mechanisms have not been clearly
elucidated.
At present, no effective therapeutic strategies have been
developed for SARS. Treatments initially used during the last
outbreak of SARS included ribavirin and corticosteroids (38,
46). Subsequently, hyper-immune globulin, protease inhibitors,
and IFNs were considered as alternative options for treating
SARS patients (57). Two groups, including our own, showed
potential effectiveness for IFN in SARS (2, 27). In one study,
IFN- was shown to inhibit viral replication in vitro and to
ameliorate disease in vivo. In a second study, our group dem-
onstrated the potential efficacy of IFN- in the treatment of
SARS-infected patients (27).
Coronaviruses are known to cause a broad spectrum of dis-
eases in animals, including pneumonia, hepatitis, nephritis,
enteritis, and encephalitis. The type and severity of disease are
influenced by the age and genetic background of the host, the
route of infection, and the coronavirus strain (58). Members
of the Coronaviridae family share replicative and transcrip-
tional features. In humans, coronaviruses were thought to
only cause upper respiratory infections and have only been
rarely implicated in lower respiratory tract infections (33).
Unlike influenza virus, human respiratory coronaviruses,
other than SARS-CoV, do not cause epithelial cell necrosis.
Thus, the SARS-CoV must have distinct characteristics
leading to its unique pathogenicity.
MHV has served as a model for dissecting the viral and
immunologic determinants of coronavirus disease (3, 28, 41,
53, 55). Extensive analysis of A59/JHM chimeric viruses has
demonstrated that, while the spike gene is a major determinant
of tropism and virulence in the central nervous system (39, 40),
other viral genes play major roles in determining the ability to
infect the liver (34) as well as the type and extent of both innate
and T-cell responses induced (44). Infection of mice with re-
combinant viruses in which the replicase genes of JHM and
A59 have been exchanged demonstrates that the presence of 3
structural genes rather than the replicase determines the dif-
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ferences in tropism and virulence between these strains (23).
We have demonstrated that the macrophage prothrombinase
FGL2/fibroleukin is an important determinant of disease in
MHV-3-induced fulminant hepatitis and that the coronavirus
nucleocapsid gene mediates much of its effect by inducing
FGL2/fibroleukin (30, 36, 37). The MHV E gene is an inducer
of apoptosis (1), the M gene of TGEV coronavirus is an in-
ducer of IFN- (22), and expression of the HE protein en-
hances the neurovirulence of a virus expressing the MHV-
JHM spike (18). Resistance to MHV has been shown to
involve both the host innate and adaptive immune systems (29,
47, 53, 56). Animals susceptible to MHV-3 generate an early
increased proinflammatory response and predominant Th2 cy-
tokine profile leading to activation of coagulation and tissue
necrosis, whereas resistant animals generate a predominant
TH1 immune response leading to production of cytotoxic T-
lymphocyte and protective B-cell responses (4, 35, 41). In a
comparison of a highly neurovirulent recombinant JHM with
the weakly neurovirulent A59, the high lethality of the former
is associated with an inability to induce a robust CD8T cell
response (44). These studies serve as an excellent background
for the study of a SARS model in mice.
None of the reported models of SARS produce lung pathol-
ogy similar to that seen in humans and thus are best suited to
studying the inhibitory effects of antiviral agents. In this report,
we demonstrate that MHV-1 infection of inbred strains of mice
produces a lethal SARS-like disease in A/J mice with features
similar to those found in human patients, whereas other mouse
strains including C57BL/6J mice fully recover. We further de-
fine differences in cytokine and type I IFN responses in resis-
tant and susceptible mice and confirm a role for IFN in treat-
ment for the viral disease.
MATERIALS AND METHODS
Mice. Female BALB/cJ, C57BL/6J A/J, and C3H/St mice 6 to 8 weeks of age
(Charles River Laboratories and Jackson Laboratories) were maintained in mi-
croisolated cages and housed in the animal colony at Toronto General Hospital,
University of Toronto, and fed standard lab chow diet and water ad libitum. All
protocols were approved by the Animal Welfare Committee.
Virus. Parental viruses MHV-3, MHV-A59, MHV-JHM, MHV-S, and
MHV-1 were obtained from the American Type Culture Collection, Manassas,
VA. Viruses were first plaque purified and then expanded in murine 17CL1 cells.
Supernatants were collected and subsequently stored at 80°C until used. Mice
were infected with 5,000 PFU intranasally unless otherwise stated.
Cells. The origins and growth of 17Cl-1, L2, and L929 cells have been previ-
ously described (48).
Viral infection and IFN- treatment. All viral infection studies were per-
formed in a viral isolation room. Mice were anesthetized by intraperitoneal
injection with 0.2 ml (or 10% of their body weight) 10% pentobarbital diluted in
normal saline. Immediately, mice received an intranasal inoculation of 5  103
PFU MHV-1 in 50 l ice-cold Dulbecco’s modified Eagle’s medium. The virus
(5  103 PFU) was instilled into the nares, and mice were observed until the virus
was inhaled. Mice were monitored daily for symptoms of disease, including
ruffled fur, tremors, and lack of activity. Additionally, three groups of 10 A/J mice
in each were infected intranasally with MHV-1 and either mock treated with
phosphate-buffered saline (PBS) or treated with IFN-: 10 mice received 106 IU
of IFN- 24 h prior to virus infection, 10 mice received 106 IU of IFN- 12 h
post-virus infection, and 10 mice received PBS at 12 h postinfection. IFN- and
PBS were administered by intraperitoneal inoculation.
Tissue isolation. Mice were sacrificed on days 0, 2, 8, 14, and 21 postinfection.
Blood was collected via cardiac puncture, and serum was stored at 80°C. Liver,
lung, heart, kidney, spleen, and brain were collected at the times indicated for
histology, viral titers, and molecular analysis. Samples denoted for histology were
fixed in 3 ml of 10% formalin. Histology samples were processed by standard
methods. Samples for viral titers were snap-frozen in prelabeled cryovials in
liquid nitrogen and subsequently stored at 80°C.
Viral titers. Samples were homogenized in 10% ice-cold DMEM utilizing a
Polytron homogenizer (Fisher Scientific, Whitby, Ontario, Canada). Viral titers
were determined in L2 cells as described previously (24).
Western blot analysis. Lung homogenates from each mouse strain were pre-
pared for Western immunoblot analysis. Samples were processed for Western
immunoblots as described previously (58). Briefly, cell lysates were resolved by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and resolved proteins
were transferred to membranes and then immunoblotted with antibody to
MHV-1 nucleocapsid protein and visualized using chemiluminescence. -Actin
served as a loading control.
RNA extraction and cDNA synthesis. Animal tissues snap-frozen at 80°C
were thawed, and then RNA was extracted using Invitrogen TRIZOL reagent, as
per the manufacturer’s instructions. cDNA was synthesized using 1 g RNA in
the presence of random primers and Moloney murine leukemia virus reverse
transcriptase (Invitrogen, Burlington, Ontario, Canada) according to the manu-
facturer’s protocol.
Real-time PCR for detection of type I IFNs and FGL2. Reaction components
were obtained from the LightCycler FastStart DNA Master SYBR greenPLUS I
kit (Roche). The LightCycler instrument (Roche) and corresponding software
were used for all reactions. The reaction conditions used are as follows. The PCR
was performed in a final volume of 20 l containing 1  Master SYBR green-
PLUS I buffer, various amounts of primer, and 5 l of template cDNA (concen-
tration, 100 ng/ml). The following primers and reaction conditions were used for
real-time PCR: IFN-1, 5 ATGGCTAGGCTCTGTGCTTTCC 3 and 5 TCA
TTTCTCTTCTCTCAGTCTTC 3; IFN-2, 5 AAAGGGGAGCCTCCTCAT
3 and 5 TGCTTTCCTCGTGATGCTGA 3; IFN-4, 5 CATGATCCTAGT
AATGATGAGCTACTACT 3 and 5 TCAAGAGGAGGTTCCTGCATCAC
3; IFN-5, 5 CAAAGCCTGTGTGATGCAA 3 and 5 ACTCCTGCTCAAT
CTTGCCA 3; IFN-9, 5 CCTCTGCTTTCCTGATGGTCT 3 and 5 CAGT
TCCTTCATCCCG 3; IFN-11, 5 CTGGCAAGATTGAGTGAAGAAGAG
AAGGCT 3 and 5 ATAAACAAACAAATAAATAACAAATAGGTGCG 3;
IFN-12, 5 AGCAAAATGGAGAGAACTGTCATAGA 3 and 5 ATGACA
TTGCTAATTACTGTT 3; IFN-, 5 ACACAAGCTTAACCACCATGAACA
ACAGGTGGATCCTCCACGC 3 and 5 GTTAGGAATTCTCAGTTTTGG
AAGTTTCTGGTAAGTCTTCG 3; Fgl2, 5 GTCACAGCCGGTTCAAC
ATCT 3 and 5 TGTAGGCCCCACTGCTGCTC; and hypoxanthine
phosphoribosyltransferase (HPRT), 5 CAAGCTTGCTGGTGAAAAGGA 3
and 5 TGAAGTACTCATTATAGTCAAGGGCATATC 3. The annealing
temperatures and primer concentrations for the various genes utilized in real-
time PCR analysis are as follows: IFN-1, 68°C and 10 pmol; IFN-2, 65°C and
10 pmol; IFN-4, 65°C and 10 pmol; IFN-5, 65°C and 10 pmol; IFN-9, 55°C
and 10 pmol; IFN-11, 45°C and 10 pmol; IFN-12, 45°C and 10 pmol; IFN-,
60°C and 20 pmol; Fgl2, 60°C and 10 pmol; and HPRT, 60°C and 20 pmol.
Cytokine analysis. Serum cytokine levels were assayed using cytometric bead
array kits (BD Biosciences, Mississauga, Ontario, Canada): a Th1/Th2 cytokine
kit which detects IL-2, IL-4, IL-5, tumor necrosis factor alpha (TNF-), and
IFN- and an inflammation kit which detects IL-6, IL-10, CCL2 (MCP-1),
IFN-, TNF-, and IL-12p70. Serum samples were processed as per the manu-
facturer’s instructions and analyzed using a Becton Dickinson FACScan flow
cytometer.
Immunohistochemistry and in situ hybridization. (i) Double-staining immu-
nohistochemistry to detect fgl2 and fibrin. Immunohistochemical staining for
detection of the fgl2 prothrombinase was used to assess fgl2 prothrombinase
expression in lung tissue. Tissues were fixed with 100% methanol prior to im-
munostaining. A polyclonal antibody to fgl2 prothrombinase was produced
in rabbits by repeated injections with a 14-amino-acid hydrophilic peptide
(CKLQADDHRD-PGGN) from exon 1 of the fgl2 prothrombinase, which had
been coupled to keyhole limpet hemocyanin. Antibody was purified by affinity
columns, and, thereafter, tissue or cultured cell slices were incubated with anti-
body (20 g/ml in PBS). For fibrin detection, a rabbit antifibrinogen antibody
(DakoCytomation, Carpinteria, Calif.) was utilized. Dual staining for fgl2 and
fibrin was performed using a Vecastain ABC kit (Vector Laboratories, Burlin-
game, Calif.) with the second antibodies labeled with alkaline phosphatase or
horseradish peroxidase, respectively. Subsequently, sections were incubated with
immunoperoxidase-conjugated goat immunoglobulin G (6.7 g/ml). Sections
were photographed with a Leitz Laborlux fluorescence S microscope.
(ii) Immunohistochemical staining for the infiltrating cells in lung tissue.
Infiltrating cells in lung tissue from A/J mice were characterized both prein-
fection (day 0) and on days 2 and 8 post-MHV-1 infection by indirect immu-
nohistochemistry using a standard avidin-biotin complex (ABC) immunoper-
oxidase method. A rat anti-mouse F4/80 antigen (Serotec, Raleigh, NC) at a
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1/100 dilution for detection of macrophages, a rabbit anti-human T-cell CD3
cross-reactive with mouse (Sigma, St, Louis, Mo.) at 1/400 dilution for T
cells, a rat anti-mouse CD45R/B220 (BD Pharmingen, Mississauga, Ontario,
Canada) at a dilution of 1/50 for B cells, and a rat anti-mouse neutrophil
(Cedarlane, Mississauga, Ontario, Canada) at a dilution of 1/50 for neutro-
phils were used.
For morphometry, 10 high-power fields per slide were counted. Positive cells
were stained positive with immunoperoxidase (brown).
In situ hybridization. The method employed for in situ hybridization has been
described previously (5). A digoxigenin (DIG)-11-UTP (Roche)-labeled cDNA
probe was prepared from a cloned 169-bp fragment of mfgl2 cDNA, representing
nucleotides 756 (ACTGTGACA . . .) to 924 (. . . GAGTAAGGA). The DIG-
UTP-labeled probe concentration was determined by immunoenzymatic reaction
with chemiluminescent detection, and the probes were stored at 80°C. Tissue
sections were deparaffinized in 100% xylene and 100% alcohol, followed by
prehybridization in 50% formamide and 2 SSC (1 SSC is 0.15 M NaCl plus
0.015 M sodium citrate). The hybridization mixture consisted of 50% deionized
formamide, 5% dextran sulfate, 250 g of salmon sperm DNA per milliliter, and
2 g of DIG-labeled cDNA probe per milliliter in 2 SSC. The hybridization
mixture with the probe was denatured by heating in an 85°C water bath and
added to tissue sections for hybridization at 42°C overnight. Hybridization was
followed by application of 3% blocking reagent and incubation with polyclonal
anti-DIG Fab conjugated to alkaline phosphatase. Sections were counterstained
with methylene green and mounted with Permount (Fisher Scientific, Whitby,
Ontario, Canada) for viewing.
Electron microscopy. (i) Transmission electron microscopy sample prepara-
tion. Electron microscopy was performed on lung samples stored at 4°C in
fixative (2.5% glutaldehyde, 3.2% paraformaldehyde, 1.0 M phosphate buffer,
pH 7.2). Samples were postfixed with 1% osmium tetroxide diluted in phos-
phate buffer, followed by en bloc staining with 2.5% uranyl acetate. Samples
were then dehydrated using a graded series of ethanol and treated with
propylene oxide. Epoxy resin Epon-Araldite was used as the embedding
material, and sections were cut on a Riechert Ultracut E microtome and
collected on 300 mesh copper grids. Samples were stained using uranyl
acetate followed by Reynold’s lead citrate. Grids were analyzed with a Hitachi
H7000 electron microscope at 75 kV.
(ii) Immunogold electron microscopy. Tissues were fixed in 4% paraformal-
dehyde and 0.1% glutaraldehyde in 0.1 M phosphate buffer, pH 7.4, and then
minced to 1-mm3 cubes in phosphate buffer, infused with 2.3 M sucrose prior to
freezing in liquid nitrogen. Samples were then stored at 85°C for 48 h in a
solution of absolute methanol containing 0.5% uranyl acetate. The samples were
warmed to 20°C and then infiltrated with Lowicryl HM20 (Marivac Services,
Halifax, Nova Scotia, Canada) and embedded and polymerized in the cold with
UV. Ultrathin sections were mounted on Formvar-coated nickel grids. The
sections were incubated with antibody against MHV-N (nucleocapsid protein)
followed by incubation with goat anti-murine immunoglobulin G–10-nm gold
particle complexes (GE Healthcare, Piscataway, N.J.) and stained with uranyl
acetate. The grids were examined using a JEOL JEM 1240 electron microscope
(JEOL, Tokyo, Japan).
RESULTS
MHV-1 produces SARS-like pulmonary disease in BALB/cJ
mice. In a first set of experiments, we examined the ability of a
large number of murine coronavirus strains, including MHV-1,
MHV-A59, MHV-JHM, MHV-S, and MHV-3 to produce
SARS-like pathology (Table 1). BALB/cJ mice were initially
studied as they are known to be highly susceptible to many
MHV strains when infected by the intraperitoneal and intra-
cerebral routes. BALB/cJ mice inoculated with 105 PFU of
MHV-1 intranasally developed pulmonary disease with partial
characteristic features of human SARS, including interstitial
pulmonary infiltrates, hyaline membranes, giant cells, conges-
tion, and hemorrhage (Fig. 1a). In addition to diffuse pulmo-
nary infiltrates, a few focal deposits of fibrin were seen around
small arterial blood vessels and in alveolar spaces with entrap-
ment of platelets. Changes were noted as early as 2 days postin-
fection and progressed to day 14. Clinically these mice became
lethargic with rapid respiration, but all mice survived and pul-
monary pathology resolved by day 21. Livers of MHV-1-in-
fected BALB/cJ mice sacrificed on day 8 showed portal infil-
trates which by day 14 progressed to portal-portal bridging
(data not shown). In contrast, BALB/cJ mice inoculated intra-
nasally with MHV-S and MHV-JHM developed neither liver
nor lung pathology. Although MHV-3 and MHV-A59 pro-
duced pulmonary lesions, these were milder than those gener-
ated by MHV-1 and did not have the characteristics of lesions
described in SARS-infected patients. In addition, MHV-A59-
and MHV-3-infected mice all developed severe hepatic necro-
sis and died of liver failure by day 10, and thus these strains of
MHV do not represent relevant models of SARS. Taken to-
gether, these studies suggested that MHV-1 produced a mild
SARS-like disease in BALB/cJ mice, a mild but significant liver
injury, but the disease was transitory and all of the infected
mice survived.
MHV-1 infection of A/J mice produces clinical and patho-
logical SARS-like disease with high mortality. Since the
C57BL/6J, C3H/St, and A/J strains have previously been shown
to exhibit various degrees of susceptibility to other coronavi-
ruses, including MHV-3 and MHV-A59, we inoculated all of
these strains of mice with MHV-1 intranasally. MHV-1-in-
fected C57BL/6J mice developed only mild pulmonary disease
TABLE 1. Ability of strains of MHV to produce SARS lung pathology in BALB/cJ mice
Classical feature of SARS
Histopathology of straina:
MHV-3 MHV-A59 MHV-1 MHV-S MHV-JHM
Congestion     
Edema  Few foci  
Hyaline membrane     
Interstitial thickening Limited    
Interstitial inflammation   Focal  
Alveolar infiltrate     
Bronchus Normal Mild peribronchial
inflammation
Resolving peribronchial
inflammation
 
Pattern of disease Pneumonitis Focal inflammation SARS-like (reversible) Pneumonitis Normal
a Shown is a summary of histopathological findings in BALB/cJ mice infected with different strains of MHV, including MHV-3, MHV-A59, MHV-1, MHV-S, and
MHV-JHM. Scores:, absent;, mild;, moderate;, severe. Based on the findings, MHV-1 produces the histopathologic picture most compatible with human
SARS.
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similar to that seen in BALB/cJ mice by day 2 postinfection.
The pulmonary disease progressed to day 8, but by day 14
postinfection, the pulmonary lesions improved and completely
resolved (data not shown).
In contrast, A/J mice developed severe progressive pulmo-
nary disease by day 2 post-MHV-1 infection and all MHV-1-
infected A/J mice died within 7 to 10 days of infection. On day
2, patchy interstitial alveolar thickening and fluid accumulation
in alveolar spaces (pulmonary edema) were prominent. At
death, lungs showed severe interstitial pneumonitis with large
areas of complete consolidation of the lungs. The interstitial
inflammatory reaction included hyaline membranes, fibrin
deposition, and heavy lymphocyte and macrophage infiltrates
(Fig. 1b and c). By immunohistochemistry, infiltrating cells in
MHV-1-infected lung tissue from A/J mice were predomi-
nantly macrophages and neutrophils on both day 2 and day 6
post-MHV-1 infection, as determined by morphometric anal-
ysis. T cells (CD3 positive) were also increased in the infil-
trates, especially by day 6 postinfection. In contrast, B cells
were relatively unchanged. (Fig. 2a and b).
Examination of the livers of MHV-1-infected A/J mice
showed near normal histology to day 6, but on day 7 just prior
to death, there was severe hepatic congestion compatible with
lung and heart failure as described in humans (data not
shown).
Following infection with MHV-1, C3H/St mice showed an
intermediate pattern of resistance/susceptibility and surviving
C3H mice went on to develop chronic pulmonary changes
including fibrosis and bronchial hyperplasia (data not shown).
Thus, A/J mice are highly susceptible to MHV-1-induced pul-
monary disease when the virus is delivered intranasally,
C57BL/6J are relatively resistant, and C3H mice have an in-
termediate susceptibility.
A/J, C3H/St, BALB/cJ, and C57BL/6J mice (n 	 10 per
FIG. 1. Histopathology of MHV lung infection. (a) Histopathology of BALB/cJ mice infected with MHV-1 showing resolving interstitial
pneumonitis. On day 2 postinfection, hemorrhage and inflammatory interstitial cell infiltrates are prominent. By day 7, hyaline membranes can be
seen (arrow), and by day 21, pneumonitis is resolving (hematoxylin and eosin stain; magnification, 200). (b) Histopathology of MHV-1-infected
A/J mice. The upper left panel represents day 0 preinfection, showing normal alveoli (hematoxylin and eosin stain; magnification, 100). The
upper right panel represents 2 days post-MHV infection, showing mononuclear infiltrates with nodular formation (hematoxylin and eosin stain;
magnification, 100). The lower left panel shows severe diffuse pneumonitis with consolidation on day 8 postinfection (magnification, 100). The
lower right panel is a close-up of the lower left panel showing mononuclear cell infiltrates and hyaline membrane (arrow) (magnification, 200).
(c) MHV-1-infected A/J mice on day 8 postinfection showing details of interstitial inflammation and hyaline membranes (arrow). The right panel
is a higher magnification (500) of the left panel (250) showing further details of hyaline membranes.
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FIG. 2. (a) Immunoperoxidase stains of infiltrating cells in lung tissues from MHV-1-infected A/J mice. Columns represent days 0, 2, and 8.
Rows represent different antibodies. Results are scored as follows: , negative; , mild positive; , moderate positive; , marked positive;
, most marked. (Top row) F4/80 macrophages. (Day 0) Lung showing normal tissue. Occasional resident macrophages in alveolar wall are
lightly stained. No infiltrate was seen. Score, /. (Day 2) Lung tissue showing moderate infiltrate of macrophages. Score, . (Day 8) Lung with
consolidated heavy infiltrate of macrophages. Score,. (Second row) CD3 T cells. (Day 0) Lung showing normal tissue with mild background
staining. Score, . (Day 2) Lung with scattering of positively stained T lymphocytes. Score, . (Day 8) Lung consolidation and numerous positive
T lymphocytes. Score,. (Third row) CD220 B cells. Lung shows occasional positive B lymphocytes. Score,. (Bottom row) Neutrophils. (Day
0) Lung with no positively stained cells in this micrograph. Score, . (Day 2) Lung infiltrate with a small number of neutrophils. Score, . (Day
8) Lung consolidation and numerous neutrophils. Score, . All micrographs are of immunoperoxidase-stained slides. Magnification, 400. (b)
Morphometric analysis for specific cell lineage infiltration. Data are expressed on the y axis as the number (mean 
 standard deviation) of positive
cells per high-power field (HPF). The number of days postinfection is given on the x axis. The lung infiltrate was a mixed-cell type with a marked
increase in macrophages (F4/80), but increases in neutrophils and T cells (CD3), especially by day 8 postinfection, were observed.
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group) were inoculated intranasally with MHV-1 (5  103
PFU) and monitored closely for clinical signs of disease and
survival (Fig. 3a). A/J mice, which are resistant to MHV-3
infection, developed clinical signs of disease within 48 h of
intranasal inoculation of MHV-1 infection and succumbed
within 8 days. In contrast, although BALB/cJ and C57BL/6J
mice developed pulmonary disease, these animals cleared virus
by day 14 and all mice survived. C3H mice developed an
intermediate pattern of susceptibility with 40% mortality (Fig.
3a). A/J mice were then inoculated with increasing concentra-
tions of MHV-1 (5  103 to 5  103 PFU) intranasally, and
survival was monitored to day 21 (Fig. 3b). In dose-response
studies, the 50% lethal dose (LD50) for A/J mice infected with
MHV-1 was calculated to equal 2.4  102 PFU using the
method of Reed and Muench (43).
Expression of FGL2/fibroleukin is associated with pulmo-
nary fibrin deposits. Fibrin deposition is a prominent feature
of SARS (7, 16). Our previous studies of coronavirus-induced
fulminant hepatitis demonstrated that cell surface expression
of the immune coagulant fgl2/fibroleukin led to organ-damag-
ing microvascular thrombosis (25, 30). We therefore examined
lung tissue from both susceptible A/J mice and resistant
C57BL/6J mice infected with MHV-1 for the presence of
FGL2 mRNA transcripts, protein, and fibrin (Fig. 4). As shown
in Fig. 4a, fgl2 protein was expressed by inflammatory cells and
type 1 pneumocytes in juxtaposition to deposits of fibrin. Fur-
thermore, by in situ hybridization, FGL2 transcripts were de-
tected in the cytoplasm of terminal alveoli and respiratory
bronchioles (Fig. 4b). Also of interest, the bronchial epithelial
cells are fused, forming giant cells, a hallmark of human SARS
(Fig. 4b). Lungs from BALB/cJ and C57BL/6 mice had neither
FGL2 nor fibrin deposits. Real-time reverse transcriptase PCR
(RT-PCR) quantification of FGL2 transcripts demonstrated
increased FGL2 mRNA expression in the lungs of A/J mice at
2 and 4 days postinfection, whereas FGL2 mRNA expression
decreased in C57BL/6J mice post-MHV-1 infection (Fig. 4c).
Virus localization and viral burden in MHV-1-infected mice.
A detailed examination of the lungs was made using transmis-
sion electron microscopy and immunogold electron micros-
copy on MHV-1 lung samples. On day 1 postinfection, virions
were identified in the peripheral airways adjacent to capillaries
in the alveolar walls (Fig. 5, left panel). A cluster of virions is
seen at the arrow. The same particles are seen at higher mag-
nification in the panel on the right. The virus particles occurred
singly or in clusters. Individual particles were easily recognized
by their uniform size and electron density. This result is im-
portant because it confirms that the virions reached the distal
airways. There is also evidence of reaction to the viruses by the
greatly enhanced vesicular activity noted in the capillary
shown; it reflects the transport of fluid across the cell, which is
greatly enhanced. It is a manifestation of edema formation,
FIG. 2—Continued.
FIG. 3. Effect of MHV-1 on survival of inbred strains of mice. (a) Effect of MHV-1 infection on survival of BALB/c, C57BL/6J, A/J, and
C3H/ST mice (n 	 10 per group). Panel b shows the effect of increasing doses of MHV-1 on survival of A/J mice. Data were used to determine
the LD50 by the method of Reed and Muench (43).
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which is an early reaction to the presence of the virus. Note
also the neutrophil in the capillary lumen. By day 4, there was
a notable infiltrate as seen also by light microscopy with lym-
phocytes, neutrophils, and macrophages. Electron microscopy
showed extensive alveolar wall damage with fibrin, cell frag-
ments, free red blood cells, virions, inflammatory cells, lym-
phocytes, macrophages, and neutrophils (not shown). By
day 8, the lung was consolidated; the electron microscopic
examination confirmed the predominance of macrophages,
which often occurred in sheets and were the predominant
cells in the infiltrate. Many cell fragments and red blood
cells were also seen; alveolar walls were largely destroyed. A
striking finding was that the macrophages were filled with
viral particles. Measurement of the particles using the elec-
tron microscope point-to-point measurement software con-
firmed the correct measurement of the particles as expected
for coronavirus virions. To further confirm that they were
indeed coronaviruses, immunoelectron microscopy was
done, which confirmed their presence, their size, and their
occurrence within macrophages. Note the presence of gold-
labeled antibodies localized to the particles within macro-
phages. This is a very heavy infection of viruses; each mac-
rophage is filled with virions. (Fig. 5)
Viral burden in lung, brain, spleen, and liver from both
C57BL/6J and A/J mice was determined, using a standard
plaque assay, as described previously (24). Virus was first de-
tected in the lungs of A/J mice at 12 h postinfection, reached
maximal levels by 48 to 72 h, and persisted at high levels until
death of the animals on day 7 postinfection (Fig. 6a, left panel).
Although virus was also recovered from the brain, liver, and
spleen of MHV-1-infected A/J mice, it was detected later in
the course of disease and at 4- to 5-log-fold-lower levels than
FIG. 4. Localization of fibrinogen-like protein (fgl2) and fibrin by immunohistochemistry and in situ hybridization in lung tissues from
MHV-1-infected A/J mice 2 days postinfection. (a) By immunohistochemistry, bronchial epithelium is positive for fgl2 protein (blue staining, single
arrow); dense fibrin deposits are seen along the wall of the bronchial (red staining, double arrow) (magnification, 400). (b) FGL2 mRNA
transcripts are seen in bronchial lining cells (blue staining, single arrow); many are fused, forming giant cells (magnification, 400). (c) The
increased number of FGL2 mRNA transcripts in lung of MHV-1-infected A/J mice was determined by real-time PCR. In contrast, no increase in
FGL2 mRNA transcripts was seen in lung in C57BL/6J mice. Data represent the mean 
 standard deviation of three independent experiments
done in triplicate.
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that seen in lung tissue (Fig. 6a, left panel). Virus was also
detected in the lungs of disease-resistant C57BL/6J mice by
12 h postinfection, but at a lower titer than in A/J mice (Fig.
6A, right panel). Maximal levels of virus were reached by day
4, but no virus was detected by day 7 to 10 postinfection.
Lung tissues were examined for the presence of nucleo-
capsid protein by Western immunoblotting (Fig. 6b). In lung
tissue from A/J mice, nucleocapsid protein was detected as
early as 12 h postinfection and persisted to time of death of
the animals on day 8 postinfection. Nucleocapsid protein
was also detected in the lungs of C57BL/6J and BALB/cJ
mice by day 2 postinfection and was detected even at 21 days
postinfection at a time when infectious virus was undetect-
able by plaque assay.
Immune response to MHV-1: proinflammatory cytokine lev-
els correlate with disease activity. In subsequent time course
experiments, we examined the cytokine expression profiles in
sera from MHV-1-infected A/J and C57BL/6 mice. Serum was
collected from A/J and C57BL/6J mice both prior to MHV-1
infection and at various times postinfection and analyzed for
IL-10, IL-6, IL-12p70, IFN-, TNF-, and macrophage che-
moattractant protein 1 (MCP-1/CCL2) (Fig. 6c). Notably, we
observed marked elevation of IL-6, IL-10, IFN-, TNF-, and
CCL2 expression in infected A/J mice compared with infected
C57BL/6 mice. In a separate set of experiments, sequential
measurements of serum levels of TNF- and IFN- were un-
dertaken in both resistant and susceptible mice (Fig. 6d). At all
time points postinfection, levels of both cytokines were higher
in susceptible A/J mice. Levels of TNF- peaked on day 6
postinfection, whereas levels of IFN- were highest at 2 days
postinfection. These results parallel observations in SARS pa-
tients.
IFN response and protective effects of IFN- in MHV-1-
infected A/J mice. To investigate the IFN response in the
differentially susceptible strains, lung tissues from MHV-1-
infected C57BL/6J and A/J mice were examined for gene ex-
pression for different IFN- subtypes and IFN-. Notably,
levels of IFN induction, as measured by gene expression, were
significantly lower in A/J than in the C57BL/6J mice (Fig. 7a).
Transcriptional activation of the early response IFNs, IFN-,
and IFN-4 was evident by 12 h postinfection, whereas gene
expression for IFN-1, IFN-2, and IFN-5 reached maximal
levels at 24 h postinfection and then returned to basal levels by
day 7 postinfection. No virus-inducible gene induction for IFN-
9, IFN-11, or IFN-12 was detectable in either mouse strain
challenged with MHV-1.
Given our observation that A/J mice exhibited lower levels
of type I IFN expression in the lung, we next examined the
effect of administering exogenous IFN- on A/J survival in
response to MHV-1 infection. In this experiment, A/J mice
were infected and either left untreated or treated with IFN-.
Two different IFN treatment regimens were employed: a single
dose of 106 U/mouse at 24 h prior to virus infection or a single
dose of 106 U/mouse 12 h post-virus challenge. As expected,
the mice in the untreated group all succumbed to MHV-1
infection by day 5 postinfection with MHV-1 (Fig. 7b). Mice
that received IFN- 12 h post-virus inoculation exhibited an
increased survival time, but all eventually succumbed to dis-
ease. Mice that were treated with IFN- 24 h prior to viral
FIG. 5. Transmission electron microscopy (TEM [A to C]) and immunoelectron microscopy (IEM [D]) detection of virions in A/J lung tissues.
(A) Virions (indicated by the arrow) are detectable in peripheral pulmonary airways; they are located outside the capillary wall of the lung on day
1. Viral particles are in close proximity to the plasma membrane of an endothelial cell within the alveolar wall. A neutrophil (darkly staining cell)
is observed within the blood vessel. (B) Higher magnification of panel A. Virions are adjacent to endothelial cell basement membranes. In addition,
vesicles are apparent in large numbers in endothelial cells of alveolar capillaries. By TEM (C), the small dense particles are virions are packed into
lysosomes within a macrophage. Virion size (as indicated, ranging from 65 to 90 nm in diameter) corresponds to MHV. By IEM (D), 10-nm gold
particles conjugated to anti-MHV nucleocapsid antibody are localized within pulmonary macrophages, confirming the viral nature of the particles.
Virion diameters are 65 to 90 nm, typical of coronaviruses.
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FIG. 6. Viral titers in tissues and cytokine responses. (a) Viral titers from lung (), brain (‚), liver (), and spleen (E) from MHV-1-infected
A/J mice and C57BL/6 mice at various times postinfection. (b) Western immunoblot detection of nucleocapsid protein in lungs. A/J mice: lane 1,
day 0; lane 2, 12 h postinfection; lane 3, 24 h postinfection; lane 4, 4 days postinfection; lane 5, 6 days postinfection; and lane 6, 8 days postinfection.
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challenge showed delayed onset of disease and an increased
survival rate.
DISCUSSION
Although a number of models for SARS have been pro-
posed, including SARS-CoV infection of mice (49), SARS-
CoV infection of cats and ferrets (31), and SARS-CoV infec-
tion of nonhuman primates (13, 32), none of the models
produce lung pathology or mortality similar to that seen in
humans. Thus, these models can be utilized at best for evalu-
ating the effectiveness of agents, including neutralizing anti-
bodies, putative vaccines, or antiviral agents on viral replica-
tion. As reported herein, the MHV-1 mouse model produces a
SARS-like clinical and pathological syndrome in which patho-
genic mechanisms can be dissected.
MHV-1 was first isolated in Mill Hill, United Kingdom, and
was reported to cause fatal hepatitis in the inbred P strain mice
(10). Even in early studies, the pathogenicity of the virus was
variable and critically dependent upon a number of immune-
modulating variables, including coinfection with enterococci
(11), Friend virus, or Moloney virus (9), and neurotropic and
pneumotropic MHV-1 variants have been described (50, 52).
Similarly, host age plays an important role in susceptibility to
the virus; C57BL/6J, C3H, P, and Swiss Webster strains of mice
have been noted to be very susceptible to intraperitoneal
MHV-1 in the first 2 weeks of life, but susceptibility decreases
as they age (10, 51, 52).
In the present study, we found that intranasal infection with
MHV-1 produces a strain-dependent disease. The A/J mice,
known to be resistant to the lethality of MHV-A59 and
MHV-3 infection, all died following intranasal infection with
MHV-1. Although BALB/cJ and C57BL/6J mice developed
pulmonary disease, these animals cleared the virus by day 14
and survived. C3H mice developed an intermediate pattern of
susceptibility with 40% mortality. The cell infiltrates seen in
MHV-1-infected A/J mice were predominantly macrophages,
with modest numbers of CD3 T cells and neutrophils similar
to that seen in human SARS (16). Peak viral titers were 104-
fold higher in susceptible A/J mice in comparison to resistant
C57BL/6J mice, an observation confirmed by lung tissue elec-
tron microscopy in which more virions were present in A/J than
C57BL/6J and BALB/cJ lung tissue cells. Interestingly, virions
were seen largely in pulmonary macrophages rather than epi-
thelial cells, consistent with our previous observations in
MHV-3-induced fulminant hepatitis. These findings argue that
host factors are critically important for the development of
SARS-like disease and suggest that, as for other coronavirus
diseases, innate immune cells are an important reservoir for
infection. The finding that pulmonary fgl2/fibroleukin is strongly
expressed in susceptible animals, but not in resistant ones, as
discussed below, is also consistent with a role for the innate
immune system in acute disease.
Serum cytokines and chemokines were markedly elevated in
susceptible A/J mice in comparison to those in resistant ani-
mals following MHV-1 infection. These findings are consistent
with other respiratory diseases. For example, the role of proin-
flammatory cytokines in respiratory infections and acute respi-
ratory distress syndrome has been previously documented (19,
45). Elevated levels of chemokines including CCL2 and CCL3
are seen in respiratory syncytial virus infections. Equally, ele-
vations in IL-1, TNF-, IFN-, and IL-12 have been reported
in mice infected with human adenovirus (17). Patients with
acute respiratory distress syndrome (ARDS) also have marked
elevations in TNF- and IL-6 (45). These elevated cytokines
and chemokines may contribute to the immunopathology of
SARS. Recently we and others have reported that serum con-
centrations of IFN-, IL-10, CXCL10, CCL5, and CXCL8
were elevated in SARS patients, especially in those patients
with a poor outcome. In SARS patients, expression levels of
IL-10, IFN-, and CXCL10 peaked within 4 days of peak viral
titers, whereas IL-12p70, IL-4, and TNF- were highest 5 to 7
days after peak viral loads. Similarly, during MHV-1 infection
of A/J mice, high levels of IFN- and TNF- were seen after
peak viral titers were observed. The fact that corticosteroids
ameliorated disease in some SARS patients is consistent with
the hypothesis that an immunopathological mechanism may
underlie the lung damage associated with SARS (54) as it is
known that corticosteroids inhibit formation of proinflam-
matory cytokines. Furthermore, it has been reported that lower
levels of both IL-6 and TNF- are associated with better re-
sponses to steroid treatment in ARDS (14, 54).
We previously reported that MHV-3 induces FGL2, an in-
flammatory immune coagulant, which results in fibrin deposi-
tion and hepatic necrosis (24, 30). In the MHV-1 model of
SARS, both FGL2 mRNA transcripts and fgl2 protein were
also seen in close association with deposits of fibrin in diseased
lungs from A/J mice, suggesting that this inflammatory medi-
ator may be contributing to the pathogenesis of SARS as well.
Previously we reported that the nucleocapsid protein from
strains of virus that caused massive hepatic necrosis, including
MHV-3 and MHV-A59, induced transcription of FGL2. At
present, we have no information whether the N gene from
MHV-1 similarly induces FGL2 transcription. More recently,
we have reported that IFN- can induce macrophage produc-
tion of FGL2 and that, although TNF- alone cannot induce
FGL2 transcription, it synergizes with IFN-, leading to a
marked enhancement in FGL2 transcription and subsequent
thrombosis (8, 24, 30). In view of the findings of marked ele-
vations of IFN- and TNF-, both in the MHV-1-induced
BALB/cJ mice: lane 1, uninfected control; lane 2, 2 days postinfection; lane 3, 8 days postinfection; lane 4, 14 days postinfection; lane 5, 21 days
postinfection. C57BL/6 mice: lane 1, uninfected control; lane 2, 2 days postinfection; lane 3, 8 days postinfection; lane 4, 14 days postinfection; lane
5, 21 days postinfection. Nucleocapsid protein was detected as a 50-kDa band. Measurement of -actin levels was performed to ensure equal
loading of protein. (c) Determination of inflammatory cytokines from uninfected and MHV-1-infected A/J and C57BL/6 lungs on day 0 or 6
postinfection. (d) Sequential measurements of serum levels of TNF- and IFN- were undertaken in both resistant and susceptible mice. At all
time points postinfection, levels of both cytokines were higher in susceptible A/J mice. Levels of TNF- peaked on day 6 postinfection, whereas
levels of IFN- were highest at 2 days postinfection.
VOL. 80, 2006 MHV-1 AS A MODEL OF HUMAN SARS 10391
 o
n
 Septem
ber 12, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
experimental model and in patients with SARS-CoV infection,
this could have relevance to disease pathogenesis.
Based on the observation that intranasal infection with
MHV-1 results in a dramatically more aggressive disease in A/J
mice versus C57BL/6J mice, we examined whether the type
and extent of the lung IFN response to infection might shape
the outcome. A/J mice displayed significantly lower levels of
type I IFN gene induction compared with C57BL/6J mice.
Gene induction for IFN-9, IFN-11, and IFN-12 was absent
in response to MHV-1 in both mouse strains. The kinetics of
gene induction, namely early expression of IFN- and IFN-4
and later gene expression of IFN-1, IFN-2, and IFN-5,
agree with the sequential phosphorylation and activation of
IRF3 followed induction and activation of IRF7. We next
examined the effect of IFN- treatment on the course of viral
disease in A/J mice. The data revealed protective effects of
IFN- treatment. Mice that received IFN- 24 h prior to virus
infection exhibited a delayed onset of disease and increased
survival. At the end of the study, mortality had decreased from
100 to 80% and 50% survival was extended from 3 to 8 days.
Mice that received IFN- 12 h post-virus infection also exhib-
ited a delayed onset of disease, but survival was unaffected.
The potential benefit of IFN treatment for respiratory corona-
virus infections was reported in patients treated with IFN
alfacon-1 during the recent SARS outbreak in Toronto. IFN
alfacon-1-treated SARS patients displayed a more rapid recov-
ery than patients treated with corticosteroids, in terms of time
taken to resolve lung abnormalities, their oxygen saturation,
their requirement for supplemental oxygen, and resolution of
clinical measurements indicative of disease severity: lactate
dehydrogenase and creatine kinase levels (29).
Although it is unclear whether SARS will continue to be a
major human health problem, the isolation of SARS-CoV
from Himalayan palm civets and bats suggests that an animal
reservoir for SARS-CoV continues to exist (21). Furthermore,
bat feces is used in traditional Chinese herbal medicines for
treatment of asthma and kidney ailments and general malaise
and additionally bat meat is a delicacy. Therefore, it is quite
possible that additional SARS outbreaks will occur.
Thus, this model offers the potential to provide further in-
sights into the pathogenesis of coronavirus-induced lung injury
and the contribution of both the virus and host immune re-
sponse. Furthermore, the data that we have generated in our
animal model has great relevance to the pathogenesis of hu-
man SARS and support a role for IFN treatment as an effective
therapy.
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